""

about | Maps & Directions | contact | admissions | faculty | alumni & development | library | Tech Support Center | dean's office | Policies & Procedures

FAculty directory

Back to alphabetical index

 

Thomas Rogers, PhD

Thomas Rogers , PhD

 

Director, Center for Inflammation, Translational and Clinical Lung Research

Professor, Pharmacology

Associate Professor, Fels Institute for Cancer Research and Molecular Biology

Telephone:  215-707-3215

Fax:  215-707-4743

Email: thomas.rogers@temple.edu

 

Department of Pharmacology

Center for Inflammation, Translational and Clinical Lung Research

Fels Institute for Cancer Research and Molecular Biology

Center for Substance Abuse Research

 

Educational Background:

 

PhD, University of Wisconsin, Madison

 

Postdoctoral Training, Roche Institute of Molecular Biology

Return to top

 

 

Research Interests:

 

Flow Cytometry

 

Our basic research interests have centered on an understanding of the cross-talk between G protein-coupled receptors (GPCRs) at the level of both protein function and gene expression.  We have focused our attention on chemokine, opioid, and formyl peptide receptors because these groups of receptors play a significant role in the regulation of inflammatory responses.

 

First, the capacity of these receptors to regulate the expression other GPCRs and their cognate ligands; and second, the cross-talk between opioid and chemokine receptor at the level of protein function.  Our studies show that activation of certain GPCRs induces the expression of several chemokines and chemokine receptors, including those chemokines that perform critical pro-inflammatory functions.  In contrast, there is a category of GPCRs which mediates anti-inflammatory responses by directly inhibiting the expression of pro-inflammatory chemokines and/or their receptors. 

 

Second, we have found that several of the GPCRs are capable of the cross-regulation of other GPCRs through a process termed “heterologous desensitization".  This process occurs when one GPCR is activated by its ligand and induces a signaling pathway which leads to the inactivation of a second, and distinct, GPCR.  Our current work suggests that it should be possible to utilize the process of heterologous desensitization to devise strategies to develop treatment therapies for a number of important disease states.

 

Return to top

 

 

PUBMED PUBLICATIONS :


Recent Medically Related Publications, Obtained from PubMed (Click on PubMed ID to view abstract)

25447673. Song C, Wang Q, Song C, Lockett SJ, Colburn NH, Li CC, Wang JM, Rogers TJ, Nucleocytoplasmic shuttling of valosin-containing protein (VCP/p97) regulated by its N domain and C-terminal region. Biochim Biophys Acta 1853:1(222-32)2015 Jan

25271293. Cabral GA, Jamerson M, Rogers TJ, Editorial: Does immune dysfunction persist into adulthood after adolescent use of marijuana? J Leukoc Biol 96:4(507-9)2014 Oct

24778447. Bednar F, Song C, Bardi G, Cornwell W, Rogers TJ, Cross-desensitization of CCR1, but not CCR2, following activation of the formyl peptide receptor FPR1. J Immunol 192:11(5305-13)2014 Jun 1

24634990. Chatila WM, Criner GJ, Hancock WW, Akimova T, Moldover B, Chang JK, Cornwell W, Santerre M, Rogers TJ, Blunted expression of miR-199a-5p in regulatory T cells of patients with chronic obstructive pulmonary disease compared to unaffected smokers. Clin Exp Immunol 177:1(341-52)2014 Jul

24152989. Zhang L, Rogers TJ, Assessment of the functional regions of the superantigen staphylococcal enterotoxin B. Toxins (Basel) 5:10(1859-71)2013 Oct 22

24090653. Cornwell WD, Lewis MG, Fan X, Rappaport J, Rogers TJ, Effect of chronic morphine administration on circulating T cell population dynamics in rhesus macaques. J Neuroimmunol 265:1-2(43-50)2013 Dec 15

23950143. Ellison S, Gabunia K, Kelemen SE, England RN, Scalia R, Richards JM, Orr AW, Traylor JG Jr, Rogers T, Cornwell W, Berglund LM, Goncalves I, Gomez MF, Autieri MV, Attenuation of experimental atherosclerosis by interleukin-19. Arterioscler Thromb Vasc Biol 33:10(2316-24)2013 Oct

22928088. Shenoy KV, Solomides C, Cordova F, Rogers TJ, Ciccolella D, Criner GJ, Low CD4/CD8 Ratio in Bronchus-Associated Lymphoid Tissue Is Associated with Lung Allograft Rejection. J Transplant 2012:(928081)2012

22926418. Zhang L, Belkowski JS, Briscoe T, Rogers TJ, Regulation of mu opioid receptor expression in developing T cells. J Neuroimmune Pharmacol 7:4(835-42)2012 Dec

21656184. Kaminsky DE, Rogers TJ, Nociceptin/orphanin FQ receptor-driven heterologous desensitization of the major HIV-1 co-receptor CXCR4. J Neuroimmune Pharmacol 6:4(546-50)2011 Dec

21454526. Song C, Rahim RT, Davey PC, Bednar F, Bardi G, Zhang L, Zhang N, Oppenheim JJ, Rogers TJ, Protein kinase Czeta mediates micro-opioid receptor-induced cross-desensitization of chemokine receptor CCR5. J Biol Chem 286:23(20354-65)2011 Jun 10

21447649. Finley MJ, Steele A, Cornwell WD, Rogers TJ, Transcriptional regulation of the major HIV-1 coreceptor, CXCR4, by the kappa opioid receptor. J Leukoc Biol 90:1(111-21)2011 Jul

20957520. Rogers TJ, Immunology as it pertains to drugs of abuse, AIDS and the neuroimmune axis: mediators and traffic. J Neuroimmune Pharmacol 6:1(20-7)2011 Mar

20952659. Happel C, Kutzler M, Rogers TJ, Opioid-induced chemokine expression requires NF-?B activity: the role of PKC?. J Leukoc Biol 89:2(301-9)2011 Feb

22069657. Cornwell WD, Rogers TJ, Uncoupling of T cell receptor zeta chain function during the induction of anergy by the superantigen, staphylococcal enterotoxin A. Toxins (Basel) 2:7(1704-17)2010 Jul

20496295. Cornwell WD, Kim V, Song C, Rogers TJ, Pathogenesis of inflammation and repair in advanced COPD. Semin Respir Crit Care Med 31:3(257-66)2010 Jun

19353346. Kim V, Kelemen SE, Abuel-Haija M, Gaughan JP, Sharafkaneh A, Evans CM, Dickey BF, Solomides CC, Rogers TJ, Criner GJ, Small airway mucous metaplasia and inflammation in chronic obstructive pulmonary disease. COPD 5:6(329-38)2008 Dec

18533278. Finley MJ, Chen X, Bardi G, Davey P, Geller EB, Zhang L, Adler MW, Rogers TJ, Bi-directional heterologous desensitization between the major HIV-1 co-receptor CXCR4 and the kappa-opioid receptor. J Neuroimmunol 197:2(114-23)2008 Jul 15

18453359. Kim V, Rogers TJ, Criner GJ, New concepts in the pathobiology of chronic obstructive pulmonary disease. Proc Am Thorac Soc 5:4(478-85)2008 May 1

18279847. Finley MJ, Happel CM, Kaminsky DE, Rogers TJ, Opioid and nociceptin receptors regulate cytokine and cytokine receptor expression. Cell Immunol 252:1-2(146-54)2008 Mar-Apr

18252865. Happel C, Steele AD, Finley MJ, Kutzler MA, Rogers TJ, DAMGO-induced expression of chemokines and chemokine receptors: the role of TGF-beta1. J Leukoc Biol 83:4(956-63)2008 Apr

18247127. Kaminsky DE, Rogers TJ, Suppression of CCL2/MCP-1 and CCL5/RANTES expression by nociceptin in human monocytes. J Neuroimmune Pharmacol 3:2(75-82)2008 Jun

17870009. Kim V, Rogers TJ, Criner GJ, Frontiers in emphysema research. Semin Thorac Cardiovasc Surg 19:2(135-41)2007 Summer

17459345. Chen X, Geller EB, Rogers TJ, Adler MW, The chemokine CX3CL1/fractalkine interferes with the antinociceptive effect induced by opioid agonists in the periaqueductal grey of rats. Brain Res 1153:(52-7)2007 Jun 11

17263642. Dimitrova DI, Reichenbach NL, Yang X, Pfleiderer W, Charubala R, Gaughan JP, Suh B, Henderson EE, Suhadolnik RJ, Rogers TJ, Inhibition of HIV type 1 replication in CD4+ and CD14+ cells purified from HIV type 1-infected individuals by the 2-5A agonist immunomodulator, 2-5A(N6B). AIDS Res Hum Retroviruses 23:1(123-34)2007 Jan

17049756. Chen X, Geller EB, Rogers TJ, Adler MW, Rapid heterologous desensitization of antinociceptive activity between mu or delta opioid receptors and chemokine receptors in rats. Drug Alcohol Depend 88:1(36-41)2007 Apr 17

16594639. Adler MW, Geller EB, Chen X, Rogers TJ, Viewing chemokines as a third major system of communication in the brain. AAPS J 7:4(E865-70)2006 Jan 6

16339779. Aksoy MO, Yang Y, Ji R, Reddy PJ, Shahabuddin S, Litvin J, Rogers TJ, Kelsen SG, CXCR3 surface expression in human airway epithelial cells: cell cycle dependence and effect on cell proliferation. Am J Physiol Lung Cell Mol Physiol 290:5(L909-18)2006 May

16204637. Adler MW, Rogers TJ, Are chemokines the third major system in the brain? J Leukoc Biol 78:6(1204-9)2005 Dec

15957958. Dimitrova DI, Yang X, Reichenbach NL, Karakasidis S, Sutton RE, Henderson EE, Rogers TJ, Suhadolnik RJ, Lentivirus-mediated transduction of PKR into CD34(+) hematopoietic stem cells inhibits HIV-1 replication in differentiated T cell progeny. J Interferon Cytokine Res 25:6(345-60)2005 Jun

15466706. Lieu YK, Kumar A, Pajerowski AG, Rogers TJ, Reddy EP, Requirement of c-myb in T cell development and in mature T cell function. Proc Natl Acad Sci U S A 101:41(14853-8)2004 Oct 12

15265667. McCarthy LE, Nitsche JF, Pintar JE, Rogers TJ, The delta-opioid receptor participates in T-cell development by promoting negative selection. J Neuroimmunol 153:1-2(91-8)2004 Aug

14741440. Rahim RT, Feng P, Meissler JJ, Rogers TJ, Zhang L, Adler MW, Eisenstein TK, Paradoxes of immunosuppression in mouse models of withdrawal. J Neuroimmunol 147:1-2(114-20)2004 Feb

14729105. Chen C, Li J, Bot G, Szabo I, Rogers TJ, Liu-Chen LY, Heterodimerization and cross-desensitization between the mu-opioid receptor and the chemokine CCR5 receptor. Eur J Pharmacol 483:2-3(175-86)2004 Jan 12

14597094. Rahim RT, Meissler JJ, Zhang L, Adler MW, Rogers TJ, Eisenstein TK, Withdrawal from morphine in mice suppresses splenic macrophage function, cytokine production, and costimulatory molecules. J Neuroimmunol 144:1-2(16-27)2003 Nov

12972507. Szabo I, Wetzel MA, Zhang N, Steele AD, Kaminsky DE, Chen C, Liu-Chen LY, Bednar F, Henderson EE, Howard OM, Oppenheim JJ, Rogers TJ, Selective inactivation of CCR5 and decreased infectivity of R5 HIV-1 strains mediated by opioid-induced heterologous desensitization. J Leukoc Biol 74:6(1074-82)2003 Dec

12726730. Steele AD, Henderson EE, Rogers TJ, Mu-opioid modulation of HIV-1 coreceptor expression and HIV-1 replication. Virology 309:1(99-107)2003 Apr 25

12669299. Szabo I, Manning MR, Radzievsky AA, Wetzel MA, Rogers TJ, Ziskin MC, Low power millimeter wave irradiation exerts no harmful effect on human keratinocytes in vitro. Bioelectromagnetics 24:3(165-73)2003 Apr

12615205. Rogers TJ, Peterson PK, Opioid G protein-coupled receptors: signals at the crossroads of inflammation. Trends Immunol 24:3(116-21)2003 Mar

12486875. Steele AD, Szabo I, Bednar F, Rogers TJ, Interactions between opioid and chemokine receptors: heterologous desensitization. Cytokine Growth Factor Rev 13:3(209-22)2002 Jun

12130663. Szabo I, Chen XH, Xin L, Adler MW, Howard OM, Oppenheim JJ, Rogers TJ, Heterologous desensitization of opioid receptors by chemokines inhibits chemotaxis and enhances the perception of pain. Proc Natl Acad Sci U S A 99:16(10276-81)2002 Aug 6

12048358. Homan JW, Steele AD, Martinand-Mari C, Rogers TJ, Henderson EE, Charubala R, Pfleiderer W, Reichenbach NL, Suhadolnik RJ, Inhibition of morphine-potentiated HIV-1 replication in peripheral blood mononuclear cells with the nuclease-resistant 2-5A agonist analog, 2-5A(N6B). J Acquir Immune Defic Syndr 30:1(9-20)2002 May 1

12044979. Rahim RT, Adler MW, Meissler JJ Jr, Cowan A, Rogers TJ, Geller EB, Eisenstein TK, Abrupt or precipitated withdrawal from morphine induces immunosuppression. J Neuroimmunol 127:1-2(88-95)2002 Jun

11878903. Wetzel MA, Steele AD, Henderson EE, Rogers TJ, The effect of X4 and R5 HIV-1 on C, C-C, and C-X-C chemokines during the early stages of infection in human PBMCs. Virology 292:1(6-15)2002 Jan 5

11727784. Szabo I, Rogers TJ, Crosstalk between chemokine and opioid receptors results in downmodulation of cell migration. Adv Exp Med Biol 493:(75-9)2001

11727782. Szabo I, Wetzel M, McCarthy L, Steele A, Henderson EE, Howard MZ, Oppenheim JJ, Rogers TJ, Interactions of opioid receptors, chemokines, and chemokine receptors. Adv Exp Med Biol 493:(69-74)2001

11727763. Eisenstein LK, MacFarland AS, Peng X, Hilburger ME, Rahim RT, Meissler LJ Jr, Rogers TJ, Wan AC, Adler MW, Effect of opioids on oral Salmonella infection and immune function. Adv Exp Med Biol 493:(169-76)2001

11727762. McCarthy LE, Rogers TJ, Alteration of early T cell development by opioid and superantigen stimulation. Adv Exp Med Biol 493:(163-7)2001

11710916. Szabo I, Wetzel MA, Rogers TJ, Cell-density-regulated chemotactic responsiveness of keratinocytes in vitro. J Invest Dermatol 117:5(1083-90)2001 Nov

11606031. Rahim RT, Meissler JJ Jr, Cowan A, Rogers TJ, Geller EB, Gaughan J, Adler MW, Eisenstein TK, Administration of mu-, kappa- or delta2-receptor agonists via osmotic minipumps suppresses murine splenic antibody responses. Int Immunopharmacol 1:11(2001-9)2001 Oct

Return to top